Angela C Cheung1, Harshna Patel2, Javier Meza-Cardona2, Maria Cino3, Sanjeev Sockalingam4, Gideon M Hirschfield5. 1. Division of Gastroenterology, Department of Medicine, Toronto Centre for Liver Disease, University of Toronto, 200 Elizabeth Street, Norman Urquhart Wing, 13th Floor, Toronto, ON, M5G 2C4, Canada. AngelaC.Cheung@uhn.ca. 2. Division of Gastroenterology, Department of Medicine, Toronto Centre for Liver Disease, University of Toronto, 200 Elizabeth Street, Norman Urquhart Wing, 13th Floor, Toronto, ON, M5G 2C4, Canada. 3. Division of Gastroenterology, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, ON, Canada. 4. Department of Psychiatry, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON, Canada. 5. Centre for Liver Research, Institute of Biomedical Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
Abstract
BACKGROUND: Primary sclerosing cholangitis (PSC) is an incurable, cholestatic liver disease often coincident with inflammatory bowel disease (IBD). AIMS: To evaluate the impact of liver disease and IBD on health-related quality of life (HRQoL) in PSC. METHODS: A mixed-methods, cross-sectional study was performed at a tertiary center. Short Form-36 (SF-36) scores were compared between PSC, Canadian normative data, and disease controls. Disease-specific instruments scores [PBC-40, Short IBD questionnaire, Liver Disease Quality of Life Questionnaire (LDQOL)] were compared between PSC and disease controls. Multivariable regression identified factors independently associated with final SF-36 component scores. Qualitative evaluation of patient questionnaires was performed using a content analysis framework. RESULTS: One hundred and sixty-two surveys were completed (99 PSC, 26 primary biliary cirrhosis, 16 non-autoimmune cholestatic liver disease, and 21 IBD). PSC patients had significantly lower SF-36 scores than Canadian controls, but similar scores to disease controls. LDQOL most accurately predicted HRQoL. Factors negatively associated with physical HRQoL included shorter IBD duration, liver disease symptoms, and decompensated cirrhosis. Mental HRQoL was influenced by liver disease and IBD symptoms, pruritus, social isolation, and depression. Nearly 75 % expressed existential anxiety regarding disease progression and diminished life expectancy, with 25 % disclosing social isolation. CONCLUSIONS: Patients with PSC have significantly lower HRQoL than healthy controls. Both symptoms of IBD and chronic liver disease impact HRQoL in patients with PSC, which lead to significant psychologic burden that is expressed by existential anxieties and social isolation. A PSC-specific HRQoL tool is critical to adequately quantify the distinct impact of IBD and cholestatic liver disease.
BACKGROUND:Primary sclerosing cholangitis (PSC) is an incurable, cholestatic liver disease often coincident with inflammatory bowel disease (IBD). AIMS: To evaluate the impact of liver disease and IBD on health-related quality of life (HRQoL) in PSC. METHODS: A mixed-methods, cross-sectional study was performed at a tertiary center. Short Form-36 (SF-36) scores were compared between PSC, Canadian normative data, and disease controls. Disease-specific instruments scores [PBC-40, Short IBD questionnaire, Liver Disease Quality of Life Questionnaire (LDQOL)] were compared between PSC and disease controls. Multivariable regression identified factors independently associated with final SF-36 component scores. Qualitative evaluation of patient questionnaires was performed using a content analysis framework. RESULTS: One hundred and sixty-two surveys were completed (99 PSC, 26 primary biliary cirrhosis, 16 non-autoimmune cholestatic liver disease, and 21 IBD). PSC patients had significantly lower SF-36 scores than Canadian controls, but similar scores to disease controls. LDQOL most accurately predicted HRQoL. Factors negatively associated with physical HRQoL included shorter IBD duration, liver disease symptoms, and decompensated cirrhosis. Mental HRQoL was influenced by liver disease and IBD symptoms, pruritus, social isolation, and depression. Nearly 75 % expressed existential anxiety regarding disease progression and diminished life expectancy, with 25 % disclosing social isolation. CONCLUSIONS:Patients with PSC have significantly lower HRQoL than healthy controls. Both symptoms of IBD and chronic liver disease impact HRQoL in patients with PSC, which lead to significant psychologic burden that is expressed by existential anxieties and social isolation. A PSC-specific HRQoL tool is critical to adequately quantify the distinct impact of IBD and cholestatic liver disease.
Entities:
Keywords:
Cholestatic liver disease; Health-related quality of life; Qualitative research; Short Form-36
Authors: Kirsten Boonstra; Karel J van Erpecum; Karin M J van Nieuwkerk; Joost P H Drenth; Alexander C Poen; Ben J M Witteman; Hans A R E Tuynman; Ulrich Beuers; Cyriel Y Ponsioen Journal: Inflamm Bowel Dis Date: 2012-03-08 Impact factor: 5.325
Authors: Johanna Haapamäki; Andrea Tenca; Harri Sintonen; Nina Barner-Rasmussen; Martti A Färkkilä Journal: Liver Int Date: 2015-01-21 Impact factor: 5.828
Authors: I M Gralnek; R D Hays; A Kilbourne; H R Rosen; E B Keeffe; L Artinian; S Kim; D Lazarovici; D M Jensen; R W Busuttil; P Martin Journal: Am J Gastroenterol Date: 2000-12 Impact factor: 10.864
Authors: Maria Benito de Valle; Monira Rahman; Björn Lindkvist; Einar Björnsson; Roger Chapman; Evangelos Kalaitzakis Journal: Clin Gastroenterol Hepatol Date: 2012-02-15 Impact factor: 11.382
Authors: W M Hopman; T Towheed; T Anastassiades; A Tenenhouse; S Poliquin; C Berger; L Joseph; J P Brown; T M Murray; J D Adachi; D A Hanley; E Papadimitropoulos Journal: CMAJ Date: 2000-08-08 Impact factor: 8.262
Authors: Elena Marcus; Paddy Stone; Anna-Maria Krooupa; Douglas Thorburn; Bella Vivat Journal: Health Qual Life Outcomes Date: 2021-03-20 Impact factor: 3.186
Authors: Wagdi Almishri; Liam A Swain; Charlotte D'Mello; Tyson S Le; Stefan J Urbanski; Henry H Nguyen Journal: Front Immunol Date: 2022-01-13 Impact factor: 7.561
Authors: Ewa Wunsch; Gary L Norman; Malgorzata Milkiewicz; Marcin Krawczyk; Chelsea Bentow; Zakera Shums; Michael Mahler; Steffi Lopens; Dirk Reinhold; Andre Franke; Christoph Schramm; Dirk Roggenbuck; Piotr Milkiewicz Journal: Aliment Pharmacol Ther Date: 2020-11-07 Impact factor: 8.171
Authors: Kim N van Munster; Marcel G W Dijkgraaf; Sara van Gennep; Ulrich Beuers; Cyriel Y Ponsioen Journal: Liver Int Date: 2020-11 Impact factor: 5.828